miRecule
$1.5Mlatest round · Venture round · Oct 2019 · 7 yr ago
$7.6Mgrants · 6 grants · CORDIS
10+team · employees, estimated range
16stories in the press
Overview
Realizing the potential of tissue-targeted RNA therapies. miRecule™ is a biotechnology company developing RNA therapies for cancer and muscular dystrophy.
Funding and backers
Total raised
$1.5M
7 rounds on record
Latest round
$1.5M
Venture round · Oct 2019 · 7 yr ago
Team
11-50
employees, estimated range
Grants
$7.6M
6 grants · CORDIS
The money's age
Long since its last round
84 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 29
Partnership miRecule Announces Strategic Collaboration with EMS Group Company Rio Biopharma to Advance Targeted Delivery of RNA Therapeutics · businesswire.com
Sep 18, 2024
Won a grant $1.8M · CORDIS
Sep 1, 2024
Won a grant $2.4M · CORDIS
Sep 20, 2021
Won a grant $739k · CORDIS
Jun 26, 2020
Won a grant $2M · CORDIS
Oct 17, 2019
Raised a round Venture round $1.5M · SEC Form D
Jul 1, 2018
Won a grant $305k · CORDIS
2018
Founded
Sep 22, 2017
Won a grant $411k · CORDIS
Funding rounds
Registers and programsofficial lists and records that name the company
| Legal entity | miRecule, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Anthony SalehExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
ProQR is a biotech company that discovers and develops unique RNA therapies for severe rare and common diseases, based in Leiden, The…
Reprogrammable RNA therapies for regeneration and longevity.. RNARevive is a science-driven biotech developing reprogrammable RNA…
US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences' Dual Signal Modulator for the Treatment of…
Our mission is to improve the treatment of Duchenne muscular dystrophy and other devastating muscle diseases by regenerating muscle with…
The unlimited potential of AI & RNA We started ShapeTX with the vision of repairing the genetic causes of disease. We’re realizing that…
Draupnir Bio is developing new innovative therapies for patients.
People
Anthony Saleh
Executive Officer
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
miRecule Announces Strategic Collaboration with EMS Group Company Rio Biopharma to Advance Targeted Delivery of RNA Therapeutics
GAITHERSBURG, Md.-(BUSINESS WIRE)-miRecule, Inc., a biotechnology company developing next-generation RNA therapeutics for rare genetic diseases, today announced a strategic research collaboration with Rio Biofarma Brasil Ltda. (RBBL), part of EMS S.A., Br
Read more
Report
miRecule Announces Strategic Collaboration with EMS Group Company Rio Biopharma to Advance Targeted Delivery of RNA Therapeutics
miRecule Announces Strategic Collaboration with EMS Group Company Rio Biopharma to Advance Targeted Delivery of RNA Therapeutics
Read more
Report
miRecule Announces Strategic Collaboration with EMS Group Company Rio Biopharma to Advance Targeted Delivery of RNA Therapeutics
Read more
Report
miRecule Announces Strategic Collaboration with EMS Group Company Rio Biopharma to Advance Targeted Delivery of RNA Therapeutics
Read more
Report
Mirecule Expands Strategic FSHD Collaboration with Sanofi
GAITHERSBURG, Md.-(BUSINESS WIRE)-Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration focuses on deliverin
Read more
Report
miRecule Selected as Featured Company Presenter at Mid Atlantic Capital Conference
GAITHERSBURG, MD - October 28, 2025 - Anthony Saleh (CEO) will present miRecule at the upcoming MACC Conference in Philadelphia on Thursday, October 30 at 12:10 PM, as part of the Healthcare-Biotech track companies presenting at the conference.
Read more
Report
miRecule to Present at the 21st Annual Meeting of the Oligonucleotide Therapeutics Society
GAITHERSBURG, MD - October 9, 2025 - miRecule, Inc. today announced that Dr. Hunter Wallace will present data from its collaboration with Sanofi at the 21st Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Budapest, Hungary. The present
Read more
Report
miRecule, Inc. Announces Issuance of New Patent Broadly Covering Lead RNA Therapeutics
GAITHERSBURG, MD - October 1, 2024 - miRecule, a biopharmaceutical company focused on developing antibody RNA conjugate-based therapeutics for rare genetic diseases and other conditions, today announced the issuance of U.S. Patent No. 12,104,157, titled "
Read more
Report
How Startup miRecule Leveraged Its RNA Platform Tech to Land a Sanofi Alliance
RNA therapies developer miRecule is partnered with Sanofi on the development of a treatment for facioscapulohumeral muscular dystrophy, or FSHD. MiRecule, winner in the biopharma track of MedCity News's Pitch Perfect startup competition, is now pursuing a
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Gaithersburg
United States
HQ
10-50 est. staff